Key Players
Competitive Landscape
Four supplier models compete in the extractable and leachable testing market: global laboratory networks, pharmaceutical testing specialists, medical-device safety laboratories and regional analytical providers.
Recent transactions and laboratory quality events changed verified capacity across regulated testing services during the current assessment period. NAMSA acquired selected Labcorp medical-device testing assets in January 2026 and added analytical plus preclinical services to its United States portfolio. Eurofins integrated its St. Louis chemistry operations in May 2026 following more than 700 ISO 10993-18 studies. Pace reported a positive FDA inspection at Research Triangle Park in July 2025 across analytical services that include E&L testing. Sponsors compare qualification depth, analytical sensitivity and continuity across toxicological review before assigning multi-stage programs.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| NAMSA completed the Labcorp medical-device testing asset acquisition in January 2026. | Device developers require coordinated analytical and preclinical support. | Consolidation concentrates biological safety capacity within specialist laboratories. | Bundled chemistry, biocompatibility and regulatory assignments. |
| Eurofins integrated its St. Louis chemistry and device-testing operations in May 2026 following more than 700 ISO 10993-18 studies. | Device sponsors require chemical characterization evidence for biological safety submissions. | Chemistry and toxicology increasingly operate within one testing network. | Complex medical-device and combination-product programs. |
| Pace reported a positive FDA inspection at Research Triangle Park in July 2025. | Pharmaceutical sponsors require inspection-ready outsourced laboratory data. | Quality history increasingly influences laboratory selection. | Container-closure, manufacturing-material and stability programs. |
SGS and Intertek compete with WuXi AppTec and Nelson Labs on qualification depth and application expertise. Element adds pharmaceutical E&L coverage from laboratories serving North American and European clients.
Source: Future Market Insights, Extractable and Leachable Testing Market and Medical Device Analytical Testing Outsourcing Market Reports, 2026-2036.
Eurofins and NAMSA cover medical-device chemistry plus toxicological interpretation within broader testing networks. Nelson Labs adds analytical coverage from facilities in North America, Europe and Asia.
Who leads the extractable and leachable testing market?
Assignment type determines which provider group holds the strongest documented position within the market. Eurofins and SGS operate broad multinational networks across pharmaceutical and medical-device testing programs. NAMSA and Nelson Labs concentrate on medical-device biological safety programs with analytical chemistry and toxicology. Intertek adds GMP pharmaceutical E&L capacity from its Reinach laboratory for Korean Pharmacopeia compliance.
Which suppliers have documented qualification or quality approvals?
Nelson Labs operates qualified laboratories across North America, Europe and Asia for pharmaceutical and medical-device analytical programs. Pace’s Research Triangle Park laboratory reported a positive FDA inspection in July 2025 and documents E&L testing for container closures and manufacturing materials.
Which companies provide pharmaceutical packaging and medical-device testing?
Eurofins, SGS and Intertek document pharmaceutical packaging plus medical-device or combination-product work. Nelson Labs and Element add chemistry programs for devices, packaging and stability assignments.
Which suppliers serve North America and Europe?
Eurofins, SGS, Intertek, Nelson Labs, Element and NAMSA document operations or client support in North America and Europe. WuXi AppTec retains China-based medical-device testing capacity serving global client programs from its domestic laboratories.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Eurofins Scientific SE | Broad pharmaceutical and medical-device testing network | Medical-device chemistry and ISO 10993-18 work. St. Louis operations integrated in May 2026. |
| SGS SA | Global testing and inspection network | Pharmaceutical manufacturing E&L expertise documented in a 2024 USP webinar and current global services. |
| Intertek Group plc | GMP pharmaceutical and product-safety testing | GMP pharmaceutical E&L with method development and toxicology. Reinach services launched in October 2025. |
| WuXi AppTec Co., Ltd. | China-based medical-device testing network | Medical-device chemistry and toxicological risk assessment. A May 2026 E&L webinar confirmed continued technical activity. |
| Nelson Laboratories, LLC | Medical-device and pharmaceutical analytical laboratory network | Medical-device and pharmaceutical analytical chemistry. Leuven added two Orbitrap systems in January 2025. |
| Pace Life Sciences, LLC | Pharmaceutical analytical testing network | Container-closure and manufacturing-material E&L. Research Triangle Park reported a positive FDA inspection in July 2025. |
| Element Materials Technology | Pharmaceutical and medical-device testing network | Pharmaceutical and medical-device E&L. A rapid-response testing service launched in March 2024. |
| NAMSA | Medical-device testing and regulatory services network | Medical-device chemistry, preclinical testing and regulatory services. Labcorp assets were acquired in January 2026. |
Research Methodology
The selected companies illustrate market structure across regulated product categories without forming a provider ranking. Inclusion requires recent evidence of E&L services or a directly relevant laboratory event. Official announcements support dated capabilities, and quality records apply to the named facility or legal entity.
